Erectile function in men with type 2 diabetes treated with dulaglutide; an exploratory analysis of the REWIND placebo-controlled randomised trial

Analysis (70.1% of original 5312 subjects) found lower incidence of erectile dysfunction (ED) in dulaglutide group vs placebo (21.3 vs 22.0/100 person-years; HR 0.92, 95% CI 0.85–0.99, p=0.021) suggesting dulaglutide might reduce incidence of ED in men with type 2 diabetes.

The Lancet Diabetes & Endocrinology